Abstract
Activation of the insulin-like growth factor-I receptor (IGF-IR) was recently shown to modulate angiogenesis by up-regulating the expression of vascular endothelial growth factor (VEGF). We hypothesized that inhibiting IGF-IR function would inhibit angiogenesis and growth of pancreatic cancer in vivo and sought to identify major signaling pathways regulated by IGF-IR in pancreatic cancer cells. Human pancreatic cancer cells (L3.6pl) were stably transfected with a dominant-negative form of IGF-IR (IGF-IR DN) or an empty vector (pcDNA). In vitro, IGF-IR DN cells exhibited a decrease in both constitutive and inducible phosphorylation of IGF-IR and Erk1/2. Constitutive expression of nuclear hypoxia-inducible factor-1alpha and secreted VEGF (P < 0.01) protein levels also were significantly lower in IGF-IR DN cells than in pcDNA cells. In vivo, IGF-IR inhibition led to decreases in pancreatic tumor volume and weight, vessel density, and tumor cell proliferation (P < 0.01 for all) and increases in tumor cell apoptosis (P < 0.02). Our results suggest that autocrine activation of the IGF-IR system significantly affects VEGF expression and angiogenesis in human pancreatic cancer. Thus, IGF-IR may be a valid target in the treatment of pancreatic cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / metabolism
-
Adenocarcinoma / pathology
-
Adenocarcinoma / physiopathology*
-
Apoptosis
-
Autocrine Communication*
-
Cell Division
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / pharmacology
-
Endothelial Growth Factors / metabolism*
-
Humans
-
Insulin-Like Growth Factor I / pharmacology
-
Intercellular Signaling Peptides and Proteins / metabolism*
-
Intracellular Membranes / metabolism
-
Isoenzymes / antagonists & inhibitors
-
Ligands
-
Lymphokines / metabolism*
-
Membrane Proteins
-
Mixed Function Oxygenases
-
Neovascularization, Pathologic*
-
Pancreatic Neoplasms / metabolism
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / physiopathology*
-
Prostaglandin-Endoperoxide Synthases
-
Receptor, IGF Type 1 / metabolism*
-
Repressor Proteins / metabolism*
-
Signal Transduction
-
Transcription Factors / metabolism*
-
Tumor Cells, Cultured
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
Substances
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Endothelial Growth Factors
-
Intercellular Signaling Peptides and Proteins
-
Isoenzymes
-
Ligands
-
Lymphokines
-
Membrane Proteins
-
Repressor Proteins
-
Transcription Factors
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factors
-
Insulin-Like Growth Factor I
-
Mixed Function Oxygenases
-
HIF1AN protein, human
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Receptor, IGF Type 1